Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Daniel Rabinowitz sold 787 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $71,916.06. Following the completion of the transaction, the insider now owns 205,552 shares of the company’s stock, valued at $18,783,341.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Daniel Rabinowitz also recently made the following trade(s):
- On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The shares were sold at an average price of $89.01, for a total value of $1,827,019.26.
- On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total value of $2,651,202.63.
Natera Price Performance
NASDAQ NTRA traded up $2.43 during midday trading on Tuesday, hitting $91.04. The company had a trading volume of 1,178,233 shares, compared to its average volume of 1,470,075. The company has a market capitalization of $10.99 billion, a PE ratio of -24.02 and a beta of 1.37. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $86.40 and a 200-day moving average price of $66.49. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82.
Hedge Funds Weigh In On Natera
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. National Bank of Canada FI bought a new position in shares of Natera in the 3rd quarter valued at $1,932,000. CWM LLC increased its stake in shares of Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 911 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Natera by 1,503.2% in the 3rd quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company’s stock valued at $4,335,000 after purchasing an additional 91,862 shares during the last quarter. Ellsworth Advisors LLC bought a new position in shares of Natera in the 3rd quarter valued at $364,000. Finally, Xponance Inc. increased its stake in shares of Natera by 1.8% in the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after purchasing an additional 261 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
NTRA has been the subject of several research analyst reports. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Tuesday. Piper Sandler lifted their target price on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Craig Hallum initiated coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 target price for the company. Canaccord Genuity Group lifted their target price on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Finally, Stephens reiterated an “overweight” rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.40.
Check Out Our Latest Research Report on Natera
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
- Five stocks we like better than Natera
- How to Read Stock Charts for Beginners
- Charles Schwab Fortifies its Uptrend on EPS Beat
- What Makes a Stock a Good Dividend Stock?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Using the MarketBeat Dividend Yield Calculator
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.